Advancing CAR T-Cell Therapy: Evidence-Based Trial Design for Chimeric Antigen Receptor T-Cell Therapy in Oncology
- PMID: 41359310
- DOI: 10.1001/jama.2025.21721
Advancing CAR T-Cell Therapy: Evidence-Based Trial Design for Chimeric Antigen Receptor T-Cell Therapy in Oncology
Plain language summary
This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer.
LinkOut - more resources
Full Text Sources
